Jakavi

Active substance

Ruxolitinib

Holder

Novartis Pharma

Status

Running

Indication

the treatment of Corticosteroid-refractory chronic graft vs. host disease after allogeneic stem cell transplantation, for pediatric patients younger than 12 years who cannot be adequately treated with commercially available alternatives

Public documents

Approbation

Approbation-Amendment_1

Information for the patient

Information for the patient-Amendment_1

Informed consent

Informed consent-Amendment_1

Last update

22/06/2023

Last updated on 13/02/2024